Pressmeddelanden

FDA CLEARS ISOFOL’S IND APPLICATION TO START CLINICAL PROGRAM WITHIN COLORECTAL CANCER WITH MODUFOLIN®

2017-01-24 08:30 CET
Isofol Medical AB announces that the US Food and Drug Administration (FDA) has cleared ...

Isofol Medical share issue oversubscribed, securing over SEK 39 million to strengthen the ongoing Phase II clinical development program of Modufolin®

2016-03-14 13:00 CET
Isofol Medical, a clinical stage pharmaceutical company, developing novel products for ...

Isofol successfully completes first dose cohort with Modufolin® as a rescue therapy in osteosarcoma patients after high dose methotrexate (HDMTX) treatment

2015-12-10 14:07 CET
Study objectives fulfilled in first dose cohort with Modufolin® as rescue therapy after...

Isofol successfully completes first dose cohort with Modufolin® as a rescue therapy in osteosarcoma patients after high dose methotrexate (HDMTX) treatment

2015-12-10 14:01 CET
Study objectives fulfilled in first dose cohort with Modufolin® as rescue therapy after...

Isofol successfully completes first dose cohort with Modufolin® as a rescue therapy in osteosarcoma patients after high dose methotrexate (HDMTX) treatment

2015-12-10 13:55 CET
Study objectives fulfilled in first dose cohort with Modufolin® as rescue therapy after...

Patent covering the use and pharmaceutical composition of Isofol’s lead Drug candidate, Modufolin®, allowed by United States Patent and Trademark Office

2015-05-28 09:22 CEST
Isofol patent covering the use and pharmaceutical composition of Modufolin® allowed by...

First patient successfully treated with Modufolin® as a rescue therapy with high dose methotrexate (HDMTX) treatment in Osteosarcoma

2015-04-14 09:00 CEST
The first patient treated with Modufolin®, as rescue therapy, after treatment with two ...

Isofol Appoints the Sage Group to Identify Strategic Partnerships for its Novel Modufolin® Chemotherapy Asset

2015-02-04 10:45 CET
Isofol Medical AB announces it has launched a global program to identify one or more st...